Neuroendocrinology
ENETS Guidelines
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin AnalogsKwekkeboom D.J.a · Krenning E.P.a · Lebtahi R.b · Komminoth P.c · Kos-Kudła B.d · de Herder W.W.e · Plöckinger U.faDepartment of Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands; bNuclear Medicine Department, Bichat Hospital, Paris, France; cInstitute for Pathology, Stadtspital Triemli, Zürich, Switzerland; dSlaska Akademia Medyczna Klinika Endokrynologii, Zabrze, Poland; eDepartment of Internal Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, The Netherlands; fDepartment of Hepatology and Gastroenterology, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Berlin, Germany
|
|
Neuroendocrinology 2009;90:220–226
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
First-Page Preview
Received: August 27, 2008
Accepted: January 27, 2009
Published online: August 28, 2009
Issue release date: August 2009
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0
ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)
For additional information: https://www.karger.com/NEN
Abstract
The purpose of this guideline is to assist physicians caring for patients with neuroendocrine tumors in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT), and in defining the minimum requirements for PRRT. This guideline also makes recommendations on what minimal patient, tumor, and treatment outcome characteristics should be reported for PRRT in order to make comparisons between studies possible. It is not this guideline’s aim to give specific recommendations on the use of specific radiolabeled somatostatin analogs for PRRT because different analogs are being used, and their availability depends on national law and local permissions.
© 2009 S. Karger AG, Basel
Related Articles:
References
- Valkema R, de Jong M, Bakker WH, et al: Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: the Rotterdam experience. Semin Nucl Med 2002;32:110–122.
- Anthony LB, Woltering EA, Espanan GD, Cronin MD, Maloney TJ, McCarthy KE: Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002;32:123–132.
- Buscombe JR, Caplin ME, Hilson AJ: Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 2003;44:1–6.
- Otte A, Herrmann R, Heppeler A, et al: Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26:1439–1447.
- Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J: The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12:941–945.
- Waldherr C, Pless M, Maecke HR, et al: Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43:610–616.
-
Waldherr C, Schumacher T, Maecke HR, et al: Does tumor response depend on the number of treatment sessions at constant injected dose using 90Yttrium-DOTATOC in neuroendocrine tumors? (abstract). Eur J Nucl Med 2002;29:S100.
- Chinol M, Bodei L, Cremonesi M, Paganelli G: Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology group. Semin Nucl Med 2002;32:141–147.
- Paganelli G, Bodei L, Handkiewicz Junak D, et al: 90Y-DOTA-D-Phe1-Tyr3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002;66:393–398.
- Bodei L, Cremonesi M, Zoboli S, et al: Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003;30:207–216.
-
Valkema R, Pauwels S, Kvols L, et al: Long-term follow-up of a phase 1 study of peptide receptor radionuclide therapy (PRRT) with [90Y-DOTA0,Tyr3]octreotide in patients with somatostatin receptor positive tumours (abstract). Eur J Nucl Med Mol Imaging 2003;30(suppl 2):S232.
- Bushnell D, O’Dorisio T, Menda Y, et al: Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. J Nucl Med 2003;44:1556–1560.
- Reubi JC, Schar JC, Waser B, et al: Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273–282.
- Kwekkeboom DJ, Bakker WH, Kooij PP, et al: [177Lu-DOTA0Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 2001;28:1319–1325.
- Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, Bakker WH, Kwekkeboom DJ: Comparison of [(177)Lu-DOTA(0), Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 2006;33:1346–1351.
- Kwekkeboom DJ, De Herder WW, Kam BL, et al: Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124–2130.
- Kwekkeboom DJ, Bakker WH, Kam BL, et al: Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417–422.
- Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al: Treatment with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate in patients with gastro-entero-pancreatic (GEP) tumors. J Clin Oncol 2005;23:2754–2762.
- De Keizer B, van Aken MO, Feelders RA, de Herder WW, Kam BL, van Essen M, Krenning EP, Kwekkeboom DJ: Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 2008;35:749–755.
- Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P: In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148–155.
-
Baum RP, Söldner J, Schmücking M, Niesen A: Peptidrezeptorvermittelte Radiotherapie (PRRT) neuroendokriner Tumoren: Klinische Indikationen und Erfahrung mit 90Yttrium-markierten Somatostatinanaloga. Onkologe 2004;10:1098–1110.
External Resources
-
Baum RP, Söldner J, Schmücking M, Niesen A: Intravenous and intra-arterial peptide receptor radionuclide therapy (PRRT) using Y-90-DOTA-Tyr3-octreotate (Y-90-DOTA-TATE) in patients with metastatic neuroendocrine tumors (abstract). Eur J Nucl Med 2004;31(suppl 2):S238.
Article / Publication Details
First-Page Preview
Received: August 27, 2008
Accepted: January 27, 2009
Published online: August 28, 2009
Issue release date: August 2009
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0
ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)
For additional information: https://www.karger.com/NEN
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
PubMed ID
